Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : A Biotech Bonanza! -- Ignore unavailable to you. Want to Upgrade?

To: Alys Hall who wrote (19)	10/22/1997 12:13:00 PM
From: Giuseppe Scalamogna	Read Replies (1) \| Respond to of 64

Alys, I hope to begin some comments on Supergen soon. Most likely Monday, October 27 we could officially begin discussions of Supergen...the first company discussed in our project. I think F. Jay Abella's valuation model is quite extensive and a good model for valuations. I did read his report and is very extensive in coverage. His work is a good starting point. GS

To: Alys Hall who wrote (19)	10/27/1997 10:37:00 PM
From: Giuseppe Scalamogna	Read Replies (1) \| Respond to of 64

Hi Alys, This company is to say the least quite fascinating. On top of that, being able to pick up shares of stock on great biotechs at 5 - 15% discounts because of a market hiccup I think is a once in a lifetime opporunity. One thing that does strike me as odd about Supergen however is the lack of analyst coverage and the thinness of trading. I think this is the one point where FJA is perhaps overlooking the fact of the relative obscurity of the company. Sure, Larry J. Ellison has taken notice and everyone has heard of Amgen but the heart of the issue here is Supergen. I raise these points because in speaking with the company, I was made aware that several analysts will be coming on line with recommendations in the very near future. I think this will fulfill F.J. Abella's criteria for well known stock more adequately and we will definetely see bounces in the price. I think something people don't take into account sometimes is the importance of analyst recommendations on stocks. Not only do they establish price targets, but their Buy/Hold/Sell recommendations are PRICED into the stock at any time as a premium. People pay EXTRA for companies that analysts like. I think this will soon be the case with Supergen. Still continuing my investigation. Will report again soon. GS